Treatments

*November 2025* The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418/DB-1418 for the treatment of patients with unresectable, locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion or exon 21 L858R mutation, whose disease has progressed on or after therapy…

*November 2025* On November 6, 2025, The National Comprehensive Cancer Network (NCCN) released their updated Clinical Practice Guidelines in Oncology for non–small cell lung cancer (NSCLC).1 Key updates in the newly released version 1.2026 from version 8.2025 include the addition of datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) as a preferred second-line regimen for…

*November 2025* While several phase II studies have demonstrated that local consolidation therapy (LCT) can improve event-free survival outcomes compared to systemic therapy alone, none have specifically evaluated primary tumor resection (PTR) in combination with EGFR TKI therapy before disease progression. Researchers evaluated whether PTR as LCT in metastatic non-small…

*December 2025* More than half of patients with EGFR-positive non-small cell lung cancer (NSCLC) will eventually develop central nervous system (CNS) metastases. Dr. Brea and his research team have already engineered a potent CAR-T cell therapy that targets TROP-2, a protein commonly found on EGFR-positive lung cancer cells and on…

*October 2025* REDMOND, Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class…

*October 2025* The addition of local consolidative therapy (LCT) to osimertinib (Tagrisso) significantly improved progression-free survival (PFS) vs osimertinib alone in patients with metastatic EGFR-mutant non–small cell lung cancer (NSCLC), even in the setting of polymetastatic disease, according to data from the phase 2 NorthStar trial (NCT03410043) presented during the 2025…

*October 2025* Zipalertinib demonstrated preliminary efficacy and was associated with low rates of treatment-related dose reductions and discontinuations in patients with non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions or other uncommon single or compound uncommon mutations and active central nervous system (CNS) metastases and/or leptomeningeal disease, according to preliminary…

*October 2025* Treatment with Sacituzumab tirumotecan (sac-TMT) led to an improvement in progression-free survival (PFS) vs chemotherapy in patients with nonsquamous non–small cell lung cancer (NSCLC) harboring EGFR mutations who disease was resistant to EGFR-TKIs, according to phase 3 results of the OptiTROP-Lung04 study (NCT05870319) that were presented during 2025 ESMO Congress.1…